The goal of this study was to assess the effects of a single injection of intravitreal ranibizumab (RAN) or bevacizumab (BEV) on the retinal vessel size in eyes with diabetic macular edema.
In total, 32 patients were enrolled in the RAN group, and 30 patients were included in BEV group. Each of these groups was also subdivided into two others groups: a study group and a control group. The study groups were composed of the injected eyes, whereas the noninjected fellow eyes served as the control groups. The patients underwent complete ophthalmic examinations, including optical coherence tomography and fundus fluorescein angiography, and the primary outcome measures included the central retinal artery equivalent, central retinal vein equivalent, and artery-to-vein ratio.
In the RAN study group (n = 32), the preinjection mean central retinal artery equivalent (175.42 μm) decreased to 169.01 μm after 1 week, and to 167.47 μm after 1 month (P < 0.001), whereas the baseline central retinal vein equivalent (235.29 μm) decreased initially to 219.90 μm after 1 week, and to 218.36 μm after 1 month (P < 0.001). In the BEV study group (n = 30), the preinjection central retinal artery equivalent (150.21 μm) decreased to 146.25 μm after 1 week, and to 145.89 μm after 1 month (P < 0.001); whereas the baseline central retinal vein equivalent (211.87 μm) decreased initially to 204.59 μm after 1 week and was 205.24 μm after 1 month (P < 0.001). The preinjection artery-to-vein ratio values changed significantly (P = 0.001) after 1 week and after 1 month in the RAN group, but no significant alteration in the artery-to-vein ratio was observed in the BEV group (P = 0.433). In both the RAN (n = 32) and BEV (n = 30) control groups, none of the 3 parameters changed throughout the study period, when compared with the baseline.
The results of this study showed that both RAN and BEV injections significantly constricted the retinal blood vessel diameters.
The study was designed to evaluate and compare the effects of a single injection of intravitreal ranibizumab or bevacizumab on the retinal vessel size in eyes with diabetic macular edema. The results of this study showed that both the ranibizumab and bevacizumab injections significantly constricted the retinal blood vessel diameters.
Department of Ophthalmology, Okmeydani Training and Research Hospital, Istanbul, Turkey.
Reprint requests: Muhammed Mustafa Kurt, MD, Samsun Gazi Devlet Hastanesi, Goz Poliklinigi, Yenidogan Mahallesi, Aziziye Caddesi, No: 86, Ilkadim, Samsun, Turkey 55070; e-mail: email@example.com
Presented in part at the European Association for Vision and Eye Research (EVER) 19th Conference, Nice, France, October 5–8, 2016.
None of the authors has any financial/conflicting interests to disclose.